Drugs / TLN-254
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07082803 | Jun 2025 → Sep 2030 expected | non-Hodgkin lymphoma | Treeline Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06733441 | Dec 2024 → Nov 2026 expected | lymphoma | Treeline Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLN-254 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06733441 ↗ |
| Route | Oral | “administered orally” NCT06733441 ↗ |